Status:
UNKNOWN
LifeChamps Feasibility Study
Lead Sponsor:
Region Stockholm
Collaborating Sponsors:
Aristotle University Of Thessaloniki
Hospital Universitario La Fe
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The purpose of this study is to collect data from various sources (PROM / PREM, sensors, journal data) to train AI based models in the LifeChamps digital platform in a pre-pilot, as well as partly imp...
Detailed Description
"The LifeChamps project (https://lifechamps.eu/) is creating a digital platform to support clinical teams to provide more integrated follow-up care to older patients with cancer. The digital platform ...
Eligibility Criteria
Inclusion
- Diagnosed with malignant melanoma (stage I-III) and undergone primary treatment within the last 36 months.
- Has completed primary and secondary cancer treatment and is now in remission (survivorship stage).
- Assessed as physically and mentally able to participate in the study
- Can read, write and understand the Swedish language
- Can bring and use their own smart phone (Android version 10 or newer) below the study
- Have 24-hour access to internet (broadband) via WiFi router in your own household and/or free 4G mobile data (sim card and 4G router will be provided if this criterion is not met)
Exclusion
- Terminal cancer stage or prognosis \<18 months from time of recruitment
- Diagnosed with severe mental illness or cognitive illness that affects the ability to participate
- Screening with Mini-Cog where the result is between 0-2
- Inability or unwillingness to provide written informed consent
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05990634
Start Date
March 1 2023
End Date
November 1 2023
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Primary Health Care Centre
Stockholm, Sweden, 11863